Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
14888 | 674 | 51.9 | 93% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | IMMUNOBIOL ROBERT H LURIE CANC | Address | 4 | 75% | 0% | 3 |
2 | EXPT CLIN NEUROL | Address | 3 | 100% | 0% | 3 |
3 | MS CLIN | Address | 2 | 16% | 2% | 13 |
4 | DT390 | Author keyword | 2 | 67% | 0% | 2 |
5 | GENET DESERT | Address | 2 | 67% | 0% | 2 |
6 | JE MCP 1 | Author keyword | 2 | 67% | 0% | 2 |
7 | NEUROLALZHEIMERS UNIT | Address | 2 | 67% | 0% | 2 |
8 | NT2 N NEURON | Author keyword | 2 | 67% | 0% | 2 |
9 | BLOOD BRAIN BARRIER | Address | 2 | 18% | 1% | 10 |
10 | MELLEN MULTIPLE SCLEROSIS TREATMENT | Address | 2 | 10% | 3% | 17 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | DT390 | 2 | 67% | 0% | 2 | Search DT390 | Search DT390 |
2 | JE MCP 1 | 2 | 67% | 0% | 2 | Search JE+MCP+1 | Search JE+MCP+1 |
3 | NT2 N NEURON | 2 | 67% | 0% | 2 | Search NT2+N+NEURON | Search NT2+N+NEURON |
4 | CCR5 DELTA 32 POLYMORPHISM | 2 | 43% | 0% | 3 | Search CCR5+DELTA+32+POLYMORPHISM | Search CCR5+DELTA+32+POLYMORPHISM |
5 | EAE MICE | 1 | 50% | 0% | 2 | Search EAE+MICE | Search EAE+MICE |
6 | GPR75 | 1 | 100% | 0% | 2 | Search GPR75 | Search GPR75 |
7 | C C CHEMOKINE RECEPTOR 2 | 1 | 40% | 0% | 2 | Search C+C+CHEMOKINE+RECEPTOR+2 | Search C+C+CHEMOKINE+RECEPTOR+2 |
8 | ADHERENT MONOCYTES | 1 | 50% | 0% | 1 | Search ADHERENT+MONOCYTES | Search ADHERENT+MONOCYTES |
9 | AMYLOID BETA NEUROTOXICITY | 1 | 50% | 0% | 1 | Search AMYLOID+BETA+NEUROTOXICITY | Search AMYLOID+BETA+NEUROTOXICITY |
10 | ANTI APOPTOTIC EFFECTS | 1 | 50% | 0% | 1 | Search ANTI+APOPTOTIC+EFFECTS | Search ANTI+APOPTOTIC+EFFECTS |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CCR5 DELETION MUTATION | 12 | 86% | 1% | 6 |
2 | ASTROCYTE EXPRESSION | 11 | 57% | 2% | 13 |
3 | MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA | 11 | 12% | 13% | 86 |
4 | BETA CHEMOKINES | 11 | 15% | 9% | 64 |
5 | RANTES MESSENGER RNA | 5 | 54% | 1% | 7 |
6 | LYMPHOID CHEMOKINES CCL19 | 5 | 45% | 1% | 9 |
7 | MURINE ASTROCYTES | 2 | 27% | 1% | 8 |
8 | JUNCTION ASSOCIATED PROTEINS | 2 | 33% | 1% | 5 |
9 | 3RD MAJOR SYSTEM | 1 | 38% | 0% | 3 |
10 | MCP 1 CCL2 | 1 | 38% | 0% | 3 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks | 2010 | 98 | 131 | 45% |
The expression and function of chemokines involved in CNS inflammation | 2006 | 149 | 55 | 44% |
The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE) | 2003 | 207 | 84 | 51% |
Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies | 2007 | 83 | 102 | 64% |
Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases | 2005 | 234 | 259 | 28% |
Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases | 2013 | 15 | 77 | 34% |
Chemokines and glial cells: A complex network in the central nervous system | 2004 | 120 | 232 | 35% |
Opinion - Chemokines: a new class of neuromodulator? | 2007 | 132 | 84 | 29% |
Chemokines in CNS injury and repair | 2012 | 35 | 198 | 17% |
Involvement of beta-chemokines in the development of inflammatory demyelination | 2005 | 23 | 67 | 76% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | IMMUNOBIOL ROBERT H LURIE CANC | 4 | 75% | 0.4% | 3 |
2 | EXPT CLIN NEUROL | 3 | 100% | 0.4% | 3 |
3 | MS CLIN | 2 | 16% | 1.9% | 13 |
4 | GENET DESERT | 2 | 67% | 0.3% | 2 |
5 | NEUROLALZHEIMERS UNIT | 2 | 67% | 0.3% | 2 |
6 | BLOOD BRAIN BARRIER | 2 | 18% | 1.5% | 10 |
7 | MELLEN MULTIPLE SCLEROSIS TREATMENT | 2 | 10% | 2.5% | 17 |
8 | MED NEUROL SERV | 1 | 33% | 0.3% | 2 |
9 | STROKE BRAIN PROTECT | 1 | 33% | 0.3% | 2 |
10 | CRICMUMRS 975UMR 7225 | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000257607 | CCR2 ANTAGONIST//CCR2//CCR2 ANTAGONISTS |
2 | 0.0000196697 | CXCR3//CXCL10//CXCL9 |
3 | 0.0000134921 | FRACTALKINE//CXCL16//CX3CR1 |
4 | 0.0000127541 | CSF CEREBROSPINAL FLUID//SOLUBLE VASCULAR CELL ADHESION MOLECULE 1 SVCAM 1//INTRAVENOUS METHYLPREDNISOLONE |
5 | 0.0000120284 | ARACHNOID GRANULATIONS//ARACHNOID VILLI//CEREBROSPINAL FLUID ABSORPTION |
6 | 0.0000109394 | EOTAXIN//CCR3//RANTES |
7 | 0.0000105001 | MONOCYTE CHEMOATTRACTANT PROTEIN 1//MCP 1 POLYMORPHISM//REGULATED UPON ACTIVATION |
8 | 0.0000092830 | SFAS APO 1//ACUTE RELAPSE//AMYLOID PEPTIDE A BETA |
9 | 0.0000091195 | DUFFY BLOOD GROUP//DARC//DUFFY ANTIGEN |
10 | 0.0000088943 | THYMUS AND ACTIVATION REGULATED CHEMOKINE//TARC//CCR4 |